For research use only. Not for therapeutic Use.
Cilgavimab（Cat No.:I042112）is an investigational monoclonal antibody being developed for the prevention and treatment of viral infections, particularly COVID-19. It targets the spike protein of the SARS-CoV-2 virus, binding to it and blocking the virus’s ability to enter human cells. Cilgavimab is part of a combination therapy with tixagevimab (known as Evusheld), designed to offer long-lasting protection against COVID-19 in high-risk individuals, including those with weakened immune systems. It is being studied for its safety, efficacy, and potential as both a preventive and therapeutic treatment option for COVID-19.
| Catalog Number | I042112 |
| CAS Number | 2420563-99-9 |
| Purity | ≥95% |
